[go: up one dir, main page]

BRPI0507586A - moduladores de receptor de quimiocina ccr5 - Google Patents

moduladores de receptor de quimiocina ccr5

Info

Publication number
BRPI0507586A
BRPI0507586A BRPI0507586-6A BRPI0507586A BRPI0507586A BR PI0507586 A BRPI0507586 A BR PI0507586A BR PI0507586 A BRPI0507586 A BR PI0507586A BR PI0507586 A BRPI0507586 A BR PI0507586A
Authority
BR
Brazil
Prior art keywords
derivatives
present
disorders
ccr5
diaza
Prior art date
Application number
BRPI0507586-6A
Other languages
English (en)
Inventor
Stephen Deems Gabriel
David Mark Rotstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0507586A publication Critical patent/BRPI0507586A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MODULADORES DO RECEPTOR DE QUIMIOCINA CCR5. A presente invenção refere-se a derivados de piperidina de fórmula l com substituintes conforme aqui definidos, que são utilizáveis no tratamento de vários distúrbios, incluindo aqueles em que a modulação de receptores de CCR5 está implicada. Mais particularmente, a presente inveção se refere a compostos de 1-oxa-3,8-diaza-espiro¢4.5!decan-2-ona e 1-oxa-3,9-diaza-espiro¢5.5!undecan-2-ona e derivados relacionados, a composições contendo e a usos desses derivados. Distúrbios que podem ser tratados ou prevenidos pelos presentes derivados incluem Hiv e infecções retrovirais geneticamente relacionadas (e a síndrome da imunodeficiência adquirida resultante, AIDS), doenças do sistema imune e doenças inflamatórias.
BRPI0507586-6A 2004-02-10 2005-02-01 moduladores de receptor de quimiocina ccr5 BRPI0507586A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54340804P 2004-02-10 2004-02-10
PCT/EP2005/000976 WO2005075484A2 (en) 2004-02-10 2005-02-01 Chemokine ccr5 receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0507586A true BRPI0507586A (pt) 2007-07-03

Family

ID=34837578

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507586-6A BRPI0507586A (pt) 2004-02-10 2005-02-01 moduladores de receptor de quimiocina ccr5

Country Status (15)

Country Link
US (2) US7332500B2 (pt)
EP (1) EP1716156A2 (pt)
JP (1) JP2007522160A (pt)
KR (1) KR100863854B1 (pt)
CN (1) CN100497346C (pt)
AR (1) AR047536A1 (pt)
AU (1) AU2005211499A1 (pt)
BR (1) BRPI0507586A (pt)
CA (1) CA2554671A1 (pt)
CO (1) CO5700742A2 (pt)
IL (1) IL176720A0 (pt)
NO (1) NO20063495L (pt)
RU (1) RU2006132465A (pt)
TW (1) TW200529857A (pt)
WO (1) WO2005075484A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
MX2007002033A (es) 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
MX2007006382A (es) * 2004-11-29 2007-07-11 Vertex Pharma Moduladores de receptores muscarinicos.
AU2006222061B2 (en) * 2005-03-03 2011-04-28 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
EP1858896B1 (en) 2005-03-08 2010-08-18 Janssen Pharmaceutica NV Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
CA2634456A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
CA2642649A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2656183A1 (en) * 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
JP2010501561A (ja) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
KR101475091B1 (ko) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체
US20100093777A1 (en) * 2007-01-25 2010-04-15 Takeda Pharmaceutical Company Limited Spiro-ring compound
BRPI0809646A2 (pt) * 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
WO2009037168A1 (en) * 2007-09-19 2009-03-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US7973162B2 (en) * 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2011519888A (ja) * 2008-05-09 2011-07-14 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環式化合物
CA2764759A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
EP2721025B1 (en) * 2011-06-16 2015-11-25 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
PT2780015T (pt) 2011-11-18 2017-03-23 Heptares Therapeutics Ltd Agonistas de recetor muscarínico m1
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
TN2018000122A1 (en) * 2015-11-16 2019-10-04 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US20220233512A1 (en) * 2020-11-03 2022-07-28 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (pt) * 1964-04-22
HU204529B (en) * 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
ES2244437T3 (es) * 1999-05-04 2005-12-16 Schering Corporation Derivados de piperazina utiles como antagonistas de ccr5.
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CN1151131C (zh) 1999-05-04 2004-05-26 先灵公司 用作ccr5拮抗剂的哌啶衍生物
AU780419C (en) 1999-12-03 2005-09-29 Ono Pharmaceutical Co. Ltd. Triazaspiro(5.5)undecane derivatives and drugs containing the same as the active ingredient
WO2001057044A1 (fr) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Derives de pyrido-oxazine
AU2001243394A1 (en) * 2000-03-02 2001-09-12 Smith Kline Beecham Corporation Compounds and methods
KR100618063B1 (ko) * 2001-05-14 2006-08-30 에프. 호프만-라 로슈 아게 1-옥사-3,9-디아자-스피로[5.5]운데칸-2-온 유도체, 및 이의 뉴로키닌 수용체 길항제로서의 용도
CA2470575C (en) 2001-12-28 2011-02-22 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators

Also Published As

Publication number Publication date
KR20060108770A (ko) 2006-10-18
US7538122B2 (en) 2009-05-26
US7332500B2 (en) 2008-02-19
TW200529857A (en) 2005-09-16
CN1918171A (zh) 2007-02-21
CO5700742A2 (es) 2006-11-30
WO2005075484A2 (en) 2005-08-18
US20050176703A1 (en) 2005-08-11
CN100497346C (zh) 2009-06-10
JP2007522160A (ja) 2007-08-09
AU2005211499A1 (en) 2005-08-18
CA2554671A1 (en) 2005-08-18
RU2006132465A (ru) 2008-03-20
AR047536A1 (es) 2006-01-25
KR100863854B1 (ko) 2008-10-15
WO2005075484A3 (en) 2005-10-20
EP1716156A2 (en) 2006-11-02
NO20063495L (no) 2006-11-01
US20080139544A1 (en) 2008-06-12
IL176720A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
BRPI0507586A (pt) moduladores de receptor de quimiocina ccr5
AR035666A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
ATE405269T1 (de) Cyclohexylverbindungen als ccr5-antagonisten
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
BR0309118A (pt) Derivados de tropano úteis em terapêutica
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
ATE528012T1 (de) Uronsäure und probiotika
NO20052739L (no) CCR5-antagonister som medikamenter
PE20090213A1 (es) Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
NO20066055L (no) Pyridinderivater
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
NO20074207L (no) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
NO20090171L (no) Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike
NO20024338D0 (no) Substituerte beta-karboliner med IKB-kinaseinhiberende aktivitet
AU2003296993A1 (en) Cyclopropyl compounds as ccr5 antagonists
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
CY1114038T1 (el) Παραγωγα ιμιδαζοπυριδινης τα οποια αναστελλουν την εκκριση γαστρικου οξεος
NO20064732L (no) Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20056030L (no) Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer
NO20073287L (no) 2,5 og 2,6-disubstituerte benzazol-analoger som proteinkinaseinhibitorer
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.